Derek J Williams1, Kathryn M Edwards2, Wesley H Self3, Yuwei Zhu4, Krow Ampofo5, Andrew T Pavia5, Adam L Hersh5, Sandra R Arnold6, Jonathan A McCullers6, Lauri A Hicks7, Anna M Bramley7, Seema Jain7, Carlos G Grijalva8. 1. Divisions of Hospital Medicine and Department of Pediatrics, Vanderbilt University School of Medicine, Vanderbilt Vaccine Research Program, Nashville, Tennessee; derek.williams@vanderbilt.edu. 2. Department of Pediatrics, Vanderbilt University School of Medicine, Vanderbilt Vaccine Research Program, Nashville, Tennessee; Infectious Diseases, Monroe Carell Jr. Children's Hospital, and. 3. Departments of Emergency Medicine. 4. Biostatistics, and. 5. Division of Infectious Diseases, and Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, Utah; 6. Division of Infectious Diseases, LeBonheur Children's Hospital, and Department of Pediatrics, University of Tennessee Health Sciences Center, Memphis, Tennessee; and. 7. Centers for Disease Control and Prevention, Atlanta, Georgia. 8. Health Policy, Vanderbilt University School of Medicine, Nashville, Tennessee;
Abstract
INTRODUCTION: The 2011 national guidelines for the management of childhood community-acquired pneumonia (CAP) recommended narrow-spectrum antibiotics (eg, ampicillin) for most children hospitalized with CAP. We assessed the impact of these guidelines on antibiotic prescribing at 3 children's hospitals. METHODS: Children hospitalized with clinical and radiographic CAP were enrolled from January 1, 2010, through June 30, 2012, at 3 hospitals in Tennessee and Utah as part of the Centers for Disease Control and Prevention Etiology of Pneumonia in the Community study. Antibiotic selection was determined by the treating provider. The impact of the guidelines and hospital-level implementation efforts was determined by assessing the monthly percentage of enrolled children receiving third-generation cephalosporins or penicillin/ampicillin. Segmented linear regression was used to compare observed antibiotic selection in the postguideline period with expected antibiotic use projected from preguideline months. RESULTS: Overall, 2121 children were included. During the preguideline period, 52.8% (interquartile range 47.8-56.6) of children with CAP received third-generation cephalosporins, whereas 2.7% (2.1, 7.0) received penicillin/ampicillin. By 9 months postguidelines, third-generation cephalosporin use declined (absolute difference -12.4% [95% confidence interval -19.8% to -5.1%]), whereas penicillin/ampicillin use increased (absolute difference 11.3% [4.3%-18.3%]). The most substantial changes were noted at those institutions that implemented guideline-related dissemination activities. CONCLUSIONS: After publication of national guidelines, third-generation cephalosporin use declined and penicillin/ampicillin use increased among children hospitalized with CAP. Changes were more apparent among those institutions that proactively disseminated the guidelines, suggesting that targeted, hospital-based efforts are important for timely implementation of guideline recommendations.
INTRODUCTION: The 2011 national guidelines for the management of childhood community-acquired pneumonia (CAP) recommended narrow-spectrum antibiotics (eg, ampicillin) for most children hospitalized with CAP. We assessed the impact of these guidelines on antibiotic prescribing at 3 children's hospitals. METHODS:Children hospitalized with clinical and radiographic CAP were enrolled from January 1, 2010, through June 30, 2012, at 3 hospitals in Tennessee and Utah as part of the Centers for Disease Control and Prevention Etiology of Pneumonia in the Community study. Antibiotic selection was determined by the treating provider. The impact of the guidelines and hospital-level implementation efforts was determined by assessing the monthly percentage of enrolled children receiving third-generation cephalosporins or penicillin/ampicillin. Segmented linear regression was used to compare observed antibiotic selection in the postguideline period with expected antibiotic use projected from preguideline months. RESULTS: Overall, 2121 children were included. During the preguideline period, 52.8% (interquartile range 47.8-56.6) of children with CAP received third-generation cephalosporins, whereas 2.7% (2.1, 7.0) received penicillin/ampicillin. By 9 months postguidelines, third-generation cephalosporin use declined (absolute difference -12.4% [95% confidence interval -19.8% to -5.1%]), whereas penicillin/ampicillin use increased (absolute difference 11.3% [4.3%-18.3%]). The most substantial changes were noted at those institutions that implemented guideline-related dissemination activities. CONCLUSIONS: After publication of national guidelines, third-generation cephalosporin use declined and penicillin/ampicillin use increased among children hospitalized with CAP. Changes were more apparent among those institutions that proactively disseminated the guidelines, suggesting that targeted, hospital-based efforts are important for timely implementation of guideline recommendations.
Authors: Rachael K Ross; Adam L Hersh; Matthew P Kronman; Jason G Newland; Talene A Metjian; A Russell Localio; Theoklis E Zaoutis; Jeffrey S Gerber Journal: Clin Infect Dis Date: 2014-01-06 Impact factor: 9.079
Authors: R Dagan; A Hoberman; C Johnson; E L Leibovitz; A Arguedas; F V Rose; B R Wynne; M R Jacobs Journal: Pediatr Infect Dis J Date: 2001-09 Impact factor: 2.129
Authors: Lee M Hampton; Monica M Farley; William Schaffner; Ann Thomas; Arthur Reingold; Lee H Harrison; Ruth Lynfield; Nancy M Bennett; Susan Petit; Kenneth Gershman; Joan Baumbach; Bernard Beall; James Jorgensen; Anita Glennen; Elizabeth R Zell; Matthew Moore Journal: J Infect Dis Date: 2011-12-07 Impact factor: 5.226
Authors: Seema Jain; Derek J Williams; Sandra R Arnold; Krow Ampofo; Anna M Bramley; Carrie Reed; Chris Stockmann; Evan J Anderson; Carlos G Grijalva; Wesley H Self; Yuwei Zhu; Anami Patel; Weston Hymas; James D Chappell; Robert A Kaufman; J Herman Kan; David Dansie; Noel Lenny; David R Hillyard; Lia M Haynes; Min Levine; Stephen Lindstrom; Jonas M Winchell; Jacqueline M Katz; Dean Erdman; Eileen Schneider; Lauri A Hicks; Richard G Wunderink; Kathryn M Edwards; Andrew T Pavia; Jonathan A McCullers; Lyn Finelli Journal: N Engl J Med Date: 2015-02-26 Impact factor: 91.245
Authors: Ross E Newman; Erin B Hedican; Joshua C Herigon; David D Williams; Arthur R Williams; Jason G Newland Journal: Pediatrics Date: 2012-02-20 Impact factor: 7.124
Authors: Mark I Neuman; Matt Hall; Adam L Hersh; Thomas V Brogan; Kavita Parikh; Jason G Newland; Anne J Blaschke; Derek J Williams; Carlos G Grijalva; Amy Tyler; Samir S Shah Journal: Pediatrics Date: 2012-10-22 Impact factor: 7.124
Authors: Charlesnika T Evans; Frances M Weaver; Thea J Rogers; Lauren Rapacki; Scott Miskevics; Bridget Hahm; Bridget Smith; Sherri L Lavela; Barry Goldstein; Stephen P Burns Journal: Top Spinal Cord Inj Rehabil Date: 2012
Authors: Derek J Williams; Matthew Hall; Jeffrey S Gerber; Mark I Neuman; Adam L Hersh; Thomas V Brogan; Kavita Parikh; Sanjay Mahant; Anne J Blaschke; Samir S Shah; Carlos G Grijalva Journal: Pediatrics Date: 2017-03-08 Impact factor: 7.124
Authors: Erik C Madsen; Emily R Levy; Kate Madden; Anna A Agan; Ryan M Sullivan; Dionne A Graham; Adrienne G Randolph Journal: Pediatr Crit Care Med Date: 2017-02 Impact factor: 3.624
Authors: Kavita Parikh; Matt Hall; Anne J Blaschke; Carlos G Grijalva; Thomas V Brogan; Mark I Neuman; Derek J Williams; Jeffrey S Gerber; Adam L Hersh; Samir S Shah Journal: J Hosp Med Date: 2016-01-13 Impact factor: 2.960
Authors: Nicole M A Le Saux; Jennifer Bowes; Isabelle Viel-Thériault; Nisha Thampi; Julie Blackburn; Melanie Buba; Mary-Ann Harrison; Nick Barrowman Journal: Paediatr Child Health Date: 2020-06-30 Impact factor: 2.253